InkVivo Technologies AG has successfully closed a CHF 1.1 million pre-seed financing round to accelerate development of its innovative drug formulation platform. The funding will primarily support clinical development of its lead drug formulations targeting anemia and the expansion of its product pipeline..

InkVivo Technologies AG成功完成了110万瑞士法郎的预种子轮融资，以加速其创新药物制剂平台的开发。这笔资金将主要用于支持其针对贫血症的主导药物制剂的临床开发，以及产品管线的扩展。

InkVivo

InkVivo

, a Swiss biotech spin-off from ETH Zurich, addresses a critical challenge in drug development: improving how medicines are formulated and delivered to enhance efficacy and patient outcomes. Its proprietary polymer platform enables faster formulation optimization and more precise delivery of oral and long-acting injectable drugs..

，这家从苏黎世联邦理工学院分拆出来的瑞士生物技术公司，解决了药物开发中的一个关键挑战：改善药物的配方和递送方式，以提高疗效和患者治疗效果。其专有的聚合物平台能够加快配方优化，并更精确地递送口服药物和长效注射药物。

The technology has been tested with a wide range of active ingredients (e.g., small molecules, biologics, and micronutrients) and it has already demonstrated sustained drug release and absorption in a pilot study with healthy volunteers.

该技术已经过多种活性成分（例如小分子、生物制品和微量营养素）的测试，并且在一项针对健康志愿者的初步研究中已经证明了持续的药物释放和吸收效果。

Operating on a B2B model, the company combines internal product development with strategic co-developments to accelerate innovation in pharmaceutical and nutraceutical sectors.

公司采用B2B模式，将内部产品开发与战略共同开发相结合，以加速制药和营养保健品领域的创新。

First pilot collaborations on track

首次试点合作按计划进行

InkVivo is currently advancing two pilot collaborations with a pharmaceutical and a nutraceutical company to accelerate product development and commercial validation. The company is also in active discussions with several international industry leaders, with some already formalized through signed Letters of Intent..

InkVivo目前正在与一家制药公司和一家营养品公司推进两项初步合作，以加速产品开发和商业验证。该公司还与数家国际行业领导者积极商讨，其中部分已通过签署意向书正式确定。

The round was led by

本轮融资由

TiVentures

天维创投

and

和

Claves Investments

克雷维斯投资公司

, with the participation of experienced business angels, underscoring strong investor confidence in InkVivo’s technology and commercial potential.

，经验丰富的商业天使参与其中，彰显了投资者对 InkVivo 技术和商业潜力的强烈信心。

“This round marks an important step for InkVivo’s mission to unlock the full therapeutic potential of active ingredients through smart formulations” said Elia Guzzi, Co-founder and CEO of InkVivo. “Our platform allows us to rethink how medicines are delivered, replacing frequent dosing and poor absorption with solutions that are more effective, longer-lasting, and easier for patients.

“这一轮标志着InkVivo通过智能配方充分释放活性成分治疗潜力使命的重要一步，” InkVivo联合创始人兼首席执行官Elia Guzzi表示。“我们的平台让我们重新思考药物的递送方式，用更有效、更持久且对患者更便利的解决方案，取代频繁给药和吸收不良的问题。”

At the same time, we help industry partners reformulate drugs faster, extend product life cycles, and unlock new IP opportunities. With this funding, we are advancing our lead product targeting anemia and scaling up new collaborations with pharmaceutical partners.”.

同时，我们帮助行业伙伴更快地改良药物，延长产品生命周期，并挖掘新的知识产权机会。通过这笔资金，我们正在推进针对贫血的主导产品，并扩大与制药合作伙伴的新合作。"

'At TiVentures, we are proud to support InkVivo Technologies at this early stage of their journey” said Lorenzo Leoni, Managing Partner of the deeptech fund TiVentures and new Board Member. “We believe InkVivo has the right combination of scientific excellence, entrepreneurial drive, versatile platform technology and market insight to become a game-changer in the smart formulation field.'.

“在TiVentures，我们很自豪能在InkVivo Technologies发展的早期阶段支持他们，” 深科技基金TiVentures的管理合伙人兼新任董事会成员洛伦佐·莱奥尼表示，“我们相信InkVivo凭借其科学卓越性、创业动力、多功能平台技术以及市场洞察力，有望成为智能配方领域的变革者。”

InkVivo is currently incubated at the USI Startup Centre and RocketHub (managed by ETH Entrepreneur Club), and supported through Innosuisse Start-up Coaching, benefiting from strategic guidance to accelerate growth and development.

InkVivo 目前在 USI 创业中心和 RocketHub（由 ETH 创业俱乐部管理）孵化，并通过 Innosuisse 初创企业辅导计划获得支持，受益于战略指导以加速成长和发展。

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或者

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送